Comparative Pharmacology
Head-to-head clinical analysis: CEDAX versus CEFADYL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEDAX versus CEFADYL.
CEDAX vs CEFADYL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ceftibuten is a third-generation cephalosporin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), particularly PBP 3, thereby inhibiting peptidoglycan cross-linking and leading to cell lysis.
Bactericidal; inhibits cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and autolysin activation.
400 mg orally once daily for 5-10 days.
1-2 g IV/IM every 6 hours for moderate to severe infections; maximum 12 g/day.
None Documented
None Documented
Terminal elimination half-life: 2.6-3.0 hours; prolonged in renal impairment (up to 10-15 hours in severe impairment)
30-60 minutes in adults with normal renal function; prolonged to 10-20 hours in end-stage renal disease. Requires dose adjustment for CrCl <30 mL/min.
Renal: 92-96% unchanged; biliary/fecal: <5%
Renal: 90-95% unchanged via glomerular filtration and tubular secretion. Biliary: <1%. Fecal: minimal.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic